<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04209712</url>
  </required_header>
  <id_info>
    <org_study_id>DS2019070101</org_study_id>
    <nct_id>NCT04209712</nct_id>
  </id_info>
  <brief_title>Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease</brief_title>
  <official_title>Phase I Clinical Trial of Haploid Donor-derived in Vitro Activated Natural Killer Cells Infusion for Patients With Minimal Residual Disease After Consolidation Therapy for Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hebei Yanda Ludaopei Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate the effectiveness and safety of haploid donor-derived in vitro
      activated natural killer(NK) cells infusion for Treating acute myeloid leukemia Patients With
      minimal residual disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients of acute myeloid leukemia after chemotherapy with MRD(minimal residual disease) will
      receive NK cell infusion combined with consolidation chemotherapy. The bone marrow morphology
      and MRD remission of the patients will be observed 15 days after the same treatment. All
      patients will be followed up for 1 year.

      NK cells are prepared in Beijing iCELL Biotechnology Co.,Ltd, which is subsidiary to Shanghai
      iCELL Biotechnology Co.,Ltd.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>haploid allogeneic NK cell therapy with chemotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minimal Residual Disease (MRD)</measure>
    <time_frame>12 months</time_frame>
    <description>MRD-negative is defined as &lt;0.1% blasts with leukemia-associated phenotype detected by flow cytometry. MRD-positive is defined as &gt;=0.1% blasts with leukemia-associated phenotype detected by flow cytometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of toxicities defined as any CTCAE (v. 4.03)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>haploid allogeneic NK cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>haploid allogeneic NK cell therapy with chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>haploid allogeneic NK cell therapy</intervention_name>
    <description>NK cells will be intravenously infused to the patient for 2 days, with following subcutaneously injection of Interleukin-2.</description>
    <arm_group_label>haploid allogeneic NK cell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed with acute myeloid leukemia;

          2. MRD after 2 course of standard chemotherapy;

          3. No plan for hematopoietic stem cell transplantation;

          4. Hemoglobin (Hb) &gt;=60g/L, white blood cell count (WBC) &gt;=2.5x10^9/L, platelet count
             &gt;=30x10^9/L;

          5. Patients have self-knowledge ability and can sign informed and voluntary consent
             forms;

          6. Patients or their clients, guardians of pediatric patients signed the informed and
             voluntary consent form and joined the study.

        Exclusion Criteria:

          1. Intracranial hypertension or unconsciousness;

          2. Symptomatic heart failure or severe arrhythmia;

          3. Respiratory failure;

          4. With other types of malignant tumor diseases;

          5. T lymphocytic acute leukemia;

          6. Diffuse intravascular;

          7. Serum creatinine and / or urea nitrogen &gt;=1.5 times the normal value;coagulation;

          8. Serum total bilirubin &gt;=1.5 times the normal value;

          9. Sepsis or other difficult-to-control infections;

         10. Uncontrollable diabetes;

         11. severe mental disorders;

         12. WHO physical status classification &gt;=3;

         13. People who are allergic to Interleukin-2;

         14. Patients after organ transplant;

         15. Pregnant and lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xian Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Yanda Ludaopei Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiang ZHU</last_name>
    <phone>+86-15900398802</phone>
    <email>zhujiang@icell.com.cn</email>
  </overall_contact>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>December 23, 2019</last_update_submitted>
  <last_update_submitted_qc>December 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

